Adaptation to ex vivo culture reduces human hematopoietic stem cell activity independently of the cell cycle.

Autor:	Johnson CS; Wellcome and Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.; Department of Haematology, University of Cambridge, Cambridge, United Kingdom.; Cell Process Development, Cell and Gene Therapy, GlaxoSmithKline, Stevenage, United Kingdom., Williams M; Wellcome and Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.; Department of Haematology, University of Cambridge, Cambridge, United Kingdom., Sham K; Wellcome and Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.; Department of Haematology, University of Cambridge, Cambridge, United Kingdom., Belluschi S; Wellcome and Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.; Department of Haematology, University of Cambridge, Cambridge, United Kingdom., Ma W; Wellcome and Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.; Department of Haematology, University of Cambridge, Cambridge, United Kingdom., Wang X; Wellcome and Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.; Department of Haematology, University of Cambridge, Cambridge, United Kingdom., Lau WWY; Wellcome and Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.; Department of Haematology, University of Cambridge, Cambridge, United Kingdom., Kaufmann KB; Princess Margaret Cancer Center, University Health Network, Toronto, Canada., Krivdova G; Princess Margaret Cancer Center, University Health Network, Toronto, Canada., Calderbank EF; Wellcome and Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.; Department of Haematology, University of Cambridge, Cambridge, United Kingdom., Mende N; Wellcome and Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.; Department of Haematology, University of Cambridge, Cambridge, United Kingdom., McLeod J; Princess Margaret Cancer Center, University Health Network, Toronto, Canada., Mantica G; Wellcome and Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.; Department of Haematology, University of Cambridge, Cambridge, United Kingdom., Li J; Wellcome and Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.; Department of Haematology, University of Cambridge, Cambridge, United Kingdom., Grey-Wilson C; Wellcome and Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.; Department of Haematology, University of Cambridge, Cambridge, United Kingdom., Drakopoulos M; Wellcome and Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.; Department of Haematology, University of Cambridge, Cambridge, United Kingdom., Basheer S; Wellcome and Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.; Department of Haematology, University of Cambridge, Cambridge, United Kingdom., Sinha S; Wellcome and Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.; Department of Haematology, University of Cambridge, Cambridge, United Kingdom., Diamanti E; Wellcome and Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.; Department of Haematology, University of Cambridge, Cambridge, United Kingdom., Basford C; Cell Process Development, Cell and Gene Therapy, GlaxoSmithKline, Stevenage, United Kingdom., Wilson NK; Wellcome and Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.; Department of Haematology, University of Cambridge, Cambridge, United Kingdom., Howe SJ; Cell Process Development, Cell and Gene Therapy, GlaxoSmithKline, Stevenage, United Kingdom., Dick JE; Princess Margaret Cancer Center, University Health Network, Toronto, Canada., Göttgens B; Wellcome and Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.; Department of Haematology, University of Cambridge, Cambridge, United Kingdom., Green AR; Wellcome and Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.; Department of Haematology, University of Cambridge, Cambridge, United Kingdom., Francis N; Cell Process Development, Cell and Gene Therapy, GlaxoSmithKline, Stevenage, United Kingdom.; Department of Gene Therapy and Regenerative Medicine, King's College London, London, United Kingdom., Laurenti E; Wellcome and Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.; Department of Haematology, University of Cambridge, Cambridge, United Kingdom.
Jazyk:	angličtina
Zdroj:	Blood [Blood] 2024 Aug 15; Vol. 144 (7), pp. 729-741.
DOI:	10.1182/blood.2023021426
Abstrakt:	Abstract: Loss of long-term hematopoietic stem cell (LT-HSC) function ex vivo hampers the success of clinical protocols that rely on culture. However, the kinetics and mechanisms through which this occurs remain incompletely characterized. In this study, through time-resolved single-cell RNA sequencing, matched in vivo functional analysis, and the use of a reversible in vitro system of early G1 arrest, we defined the sequence of transcriptional and functional events that occur during the first ex vivo division of human LT-HSCs. We demonstrated that the sharpest loss in LT-HSC repopulation capacity happens early on, between 6 and 24 hours of culture, before LT-HSCs commit to cell cycle progression. During this time window, LT-HSCs adapt to the culture environment, limit the global variability in gene expression, and transiently upregulate gene networks involved in signaling and stress responses. From 24 hours, LT-HSC progression past early G1 contributes to the establishment of differentiation programs in culture. However, contrary to the current assumptions, we demonstrated that the loss of HSC function ex vivo is independent of cell cycle progression. Finally, we showed that targeting LT-HSC adaptation to culture by inhibiting the early activation of JAK/STAT signaling improves HSC long-term repopulating function ex vivo. Collectively, our study demonstrated that controlling early LT-HSC adaptation to ex vivo culture, for example, via JAK inhibition, is critically important to improve HSC gene therapy and expansion protocols. (© 2024 American Society of Hematology. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu